{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T19:23:18Z","timestamp":1754162598143,"version":"3.41.2"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To analyse the use of prophylactic proton pump inhibitors (PPIs) and their benefits for the prevention of gastrointestinal injury and to determine the optimal course of preventive use among patients with minor ischaemic stroke (IS) and transient ischaemic attack (TIA) at low risk of gastrointestinal bleeding (GIB) treated with short-term dual-antiplatelet therapy (DAPT).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We retrospectively collected clinical data from the hospital information system (HIS) from January 2022 to December 2023. The data were collected from patients who were admitted to a tertiary hospital with a first occurrence of minor IS\/TIA diagnosed within 14 days and treated with short-term DAPT. Univariate and multivariate logistic regression analyses were used to explore the correlations between the use of PPIs, different treatment durations, and the incidence rates of GIB, gastrointestinal discomfort, other types of bleeding, and pneumonia in these patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 220 patients were included, with 52 in the PPI group (23.64%) and 168 in the non-PPI group (76.36%). The results showed that PPI use did not significantly reduce the incidence of GIB (P = 0.059) or other types of bleeding (P = 0.916) in patients who were treated with DAPT and were at low risk of GIB. The incidence of pneumonia in the PPI group was higher than that in the non-PPI group, but the difference was not statistically significant (42.86% vs. 23.00%, P = 0.840). However, PPI use significantly reduced the occurrence of gastrointestinal discomfort (P = 0.033, OR: 0.448; 95% CI: 0.215\u20130.935), with no significant difference based on treatment duration (\u22647 days vs. &amp;gt;7 days, P = 0.520).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Regular use of PPIs within the first 7 days of initiating DAPT in patients with minor IS\/TIA at low risk of GIB significantly reduces symptoms of gastrointestinal discomfort while minimizing adverse effects due to overuse of PPIs.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1644148","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T09:54:55Z","timestamp":1753869295000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["PPI in preventing gastrointestinal injury in minor ischemic stroke or TIA patients at low risk of gastrointestinal bleeding treated with short-term dual antiplatelet therapy"],"prefix":"10.3389","volume":"16","author":[{"given":"Lu","family":"Cao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kejia","family":"Quan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"597","DOI":"10.5414\/CP202533","article-title":"Overuse of proton pump inhibitors for stress ulcer prophylaxis in Jordan","volume":"54","author":"Alqudah","year":"2016","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"B3","doi-asserted-by":"publisher","first-page":"e035239","DOI":"10.1161\/JAHA.124.035239","article-title":"Proton pump inhibitors use in patients with ischemic stroke on dual antiplatelet therapy at low risk of upper gastrointestinal bleeding","volume":"14","author":"Baik","year":"2025","journal-title":"J. Am. Heart Assoc."},{"key":"B4","first-page":"615","article-title":"The cardiovascular disease Branch of the Chinese medical association and the editorial committee of the Chinese journal of cardiovascular disease. Diagnosis and treatment guidelines for non ST segment elevation acute coronary syndrome (2024)","volume":"52","year":"2024","journal-title":"Chin. J. Cardiovasc. Dis."},{"key":"B5","first-page":"173","article-title":"Guidelines for the diagnosis and treatment of acute non variceal upper gastrointestinal bleeding (Hangzhou, 2018)","year":"2019","journal-title":"Chin. J. Intern. Med."},{"first-page":"927","article-title":"General practice Branch of Chinese medical association, editorial committee of Chinese journal of general practitioners of Chinese medical association, Expert group for the compilation of primary diagnosis and treatment. Guidelines for neurological diseases guidelines for primary diagnosis and treatment of ischemic stroke","year":"2021","key":"B6"},{"key":"B7","first-page":"1071","article-title":"Cerebrovascular disease group of Chinese medical association Neurology Branch. Chinese guidelines for secondary prevention of ischemic stroke and transient ischemic attack 2022","volume":"55","year":"2022","journal-title":"Chin. J. Neurology"},{"key":"B8","first-page":"2861","article-title":"Guidelines for prevention and treatment of thrombotic diseases","volume":"98","year":"2018","journal-title":"Chin. J. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"6881","DOI":"10.3390\/jcm11236881","article-title":"Association of proton pump inhibitor prophylaxis on clinical outcome in acute ischemic stroke in China: a multicenter retrospective cohort study","volume":"11","author":"Fang","year":"2022","journal-title":"J. Clin. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3758\/bf03193146","article-title":"G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences","volume":"39","author":"Faul","year":"2007","journal-title":"Behav. Res. Methods"},{"key":"B11","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1136\/gutjnl-2013-304738","article-title":"Proton pump inhibitors and the risk of hospitalisation for community-acquired pneumonia: replicated cohort studies with meta-analysis","volume":"63","author":"Filion","year":"2014","journal-title":"Gut"},{"key":"B12","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jacc.2021.10.028","article-title":"Magnetically controlled capsule endoscopy for assessment of antiplatelet therapy-induced gastrointestinal injury","volume":"79","author":"Han","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1056\/nejmoa1800410","article-title":"Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA","volume":"379","author":"Johnston","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1001\/jamacardio.2024.4030","article-title":"Long-term aspirin vs clopidogrel after coronary stenting by bleeding risk and procedural complexity","volume":"10","author":"Kang","year":"2025","journal-title":"JAMA Cardiol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1161\/STROKEAHA.119.026655","article-title":"Cilostazol mono and combination treatments in ischemic stroke: an updated systematic review and meta-analysis","volume":"50","author":"Kim","year":"2019","journal-title":"Stroke"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e364","DOI":"10.1161\/STR.0000000000000375","article-title":"2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American heart association\/American stroke association","volume":"52","author":"Kleindorfer","year":"2021","journal-title":"Stroke"},{"key":"B17","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1001\/jamainternmed.2015.7193","article-title":"Proton pump inhibitor use and the risk of chronic kidney disease","volume":"176","author":"Lazarus","year":"2016","journal-title":"JAMA Intern. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/S0140-6736(17)30770-5","article-title":"Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study","volume":"390","author":"Li","year":"2017","journal-title":"Lancet"},{"key":"B19","first-page":"257","article-title":"Comparative study on efficacy and safety of ticagrelor and clopidogrel in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention","volume":"28","author":"Li","year":"2023","journal-title":"Chin. J. Cardiovasc. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"571605","DOI":"10.3389\/fphar.2020.571605","article-title":"A new score for predicting acute gastrointestinal bleeding in patients administered oral antiplatelet drugs","volume":"11","author":"Lv","year":"2020","journal-title":"Front. Pharmacol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1001\/jama.2020.21360","article-title":"Gastroesophageal reflux disease: a review","volume":"324","author":"Maret-Ouda","year":"2020","journal-title":"Jama"},{"key":"B22","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1007\/s00535-023-02007-5","article-title":"Proton pump inhibitor use and risk of pneumonia: a self-controlled case series study","volume":"58","author":"Maret-Ouda","year":"2023","journal-title":"J. Gastroenterol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1053\/j.gastro.2019.05.056","article-title":"Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin","volume":"157","author":"Moayyedi","year":"2019","journal-title":"Gastroenterology"},{"article-title":"National clinical guideline for stroke for the UK and Ireland","volume-title":"Intercollegiate stroke working party","year":"2023","key":"B24"},{"key":"B2","first-page":"1","article-title":"Clinical application guidelines for proton pump inhibitors (2020 edition)","volume-title":"Chin. J. Pract. Rural Dr.","year":"2021"},{"key":"B25","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1093\/intqhc\/mzaa041","article-title":"Meta-analysis of proton pump inhibitors induced risk of community-acquired pneumonia","volume":"32","author":"Nguyen","year":"2020","journal-title":"Int. J. Qual. Health Care"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e1771","DOI":"10.1212\/WNL.0000000000207747","article-title":"Cumulative use of proton pump inhibitors and risk of dementia: the atherosclerosis risk in communities study","volume":"101","author":"Northuis","year":"2023","journal-title":"Neurology"},{"key":"B27","doi-asserted-by":"publisher","first-page":"i5813","DOI":"10.1136\/bmj.i5813","article-title":"Community acquired pneumonia incidence before and after proton pump inhibitor prescription: population based study","volume":"355","author":"Othman","year":"2016","journal-title":"Bmj"},{"key":"B28","doi-asserted-by":"publisher","first-page":"51","DOI":"10.5853\/jos.2020.03391","article-title":"Residual risk and its risk factors for ischemic stroke with adherence to guideline-based secondary stroke prevention","volume":"23","author":"Pan","year":"2021","journal-title":"J. Stroke"},{"key":"B29","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/S1474-4422(23)00113-8","article-title":"Indobufen versus aspirin in patients with acute ischaemic stroke in China (INSURE): a randomised, double-blind, double-dummy, active control, non-inferiority trial","volume":"22","author":"Pan","year":"2023","journal-title":"Lancet Neurol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.4244\/EIJV9I11A226","article-title":"Cangrelor versus clopidogrel in percutaneous coronary intervention: a systematic review and meta-analysis","volume":"9","author":"Pandit","year":"2014","journal-title":"EuroIntervention"},{"key":"B31","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","article-title":"2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European society of Cardiology (ESC)","volume":"37","author":"Roffi","year":"2016","journal-title":"Eur. Heart J."},{"key":"B32","doi-asserted-by":"publisher","first-page":"e21885","DOI":"10.7759\/cureus.21885","article-title":"Co-Prescription of dual-antiplatelet therapy and proton pump inhibitors: current guidelines","volume":"14","author":"Saven","year":"2022","journal-title":"Cureus"},{"key":"B33","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/joim.12698","article-title":"Long-term use of proton pump inhibitors, dose-response relationship and associated risk of ischemic stroke and myocardial infarction","volume":"283","author":"Sehested","year":"2018","journal-title":"J. Intern. Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1093\/eurheartj\/ehz104","article-title":"Reduced risk of gastrointestinal bleeding associated with proton pump inhibitor therapy in patients treated with dual antiplatelet therapy after myocardial infarction","volume":"40","author":"Sehested","year":"2019","journal-title":"Eur. Heart J."},{"key":"B35","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1093\/ejcts\/ezx334","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS","volume":"53","author":"Valgimigli","year":"2017","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"B36","first-page":"1198","article-title":"The current research status of antiplatelet therapy related gastrointestinal injury","volume":"28","author":"Wang","year":"2013","journal-title":"Clin. Gathering"},{"key":"B37","doi-asserted-by":"publisher","first-page":"433","DOI":"10.3969\/j.issn.1673-5765.2022.06.001","article-title":"Chinese stroke report 2020","volume":"17","author":"Wang","year":"2022","journal-title":"Chin. J. Stroke"},{"key":"B38","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1097\/CM9.0000000000002741","article-title":"Changing profiles of cardiovascular disease and risk factors in China: a secondary analysis for the Global Burden of Disease Study 2019","volume":"136","author":"Wang","year":"2023","journal-title":"Chin. Med. J. Engl."},{"article-title":"Clinical efficacy study of PPI in preventing complications of antiplatelet therapy after PCI","year":"2023","author":"Wang","key":"B39"},{"key":"B40","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"467","DOI":"10.4236\/wjcd.2018.810046","article-title":"Risk factors for gastrointestinal injuries in acute coronary syndrome patients with double antiplatelet therapy in one-year follow-up","volume":"8","author":"Zhong","year":"2018","journal-title":"World J. Cardiovasc. Dis."},{"key":"B42","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.mayocp.2021.11.037","article-title":"Proton pump inhibitors and in-hospital gastrointestinal bleeding in patients with acute coronary syndrome receiving dual antiplatelet therapy","volume":"97","author":"Zhou","year":"2022","journal-title":"Mayo Clin. Proc."},{"key":"B43","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1186\/s13063-022-06464-w","article-title":"Proton pump inhibitor in the prevention of upper gastrointestinal mucosal injury associated with dual antiplatelet therapy after coronary artery bypass grafting (DACAB-GI-2): study protocol for a randomized controlled trial","volume":"23","author":"Zhu","year":"2022","journal-title":"Trials"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1644148\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T09:54:58Z","timestamp":1753869298000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1644148\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,30]]},"references-count":43,"alternative-id":["10.3389\/fphar.2025.1644148"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1644148","relation":{},"ISSN":["1663-9812"],"issn-type":[{"type":"electronic","value":"1663-9812"}],"subject":[],"published":{"date-parts":[[2025,7,30]]},"article-number":"1644148"}}